LZM 012
Alternative Names: LZM-012Latest Information Update: 06 Dec 2023
At a glance
- Originator Livzon Pharmaceuticals
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Psoriasis
- Phase II Immunological disorders